Understanding The Role of RSF1 in HCC: Potential Drug Target Or Biomarker

Target Name: RSF1

NCBI ID: G51773

RSF1

Understanding The Role of RSF1 in HCC: Potential Drug Target Or Biomarker

RSF1 (HBV pX associated protein-8) is a protein that is expressed in the hepatocellular carcinoma (HCC) and is associated with the hepatitis B virus (HBV). The protein is expressed in the cytoplasm of HBV- infected cells and has been shown to play a role in the development and progression of HCC.

Recent studies have suggested that RSF1 may be a potential drug target or biomarker for the treatment of HCC. One study published in the journal Oncogene found that inhibition of RSF1 reduced the growth of HCC cells and improved the survival of animals with HCC. Another study published in the journal Nature Communications found that RSF1 was overexpressed in HCC tissues and was associated with the development of advanced stages of HCC.

Despite these promising findings, more research is needed to fully understand the role of RSF1 in HCC. One reason for this is that the exact mechanism by which RSF1 contributes to the development and progression of HCC is not well understood. It is possible that RSF1 plays a role in the regulation of cellular processes that are important for the development of HCC, such as cell growth, apoptosis, and angiogenesis.

Another potential mechanism by which RSF1 may contribute to the development of HCC is by promoting the growth and survival of cancer cells. Studies have shown that RSF1 can promote the growth of multiple types of cancer cells, including breast, lung, and ovarian cancer cells. This suggests that RSF1 may be a potential drug target or biomarker for cancer, including HCC.

In addition to its potential role in cancer, RSF1 is also of interest as a potential drug target for other diseases. For example, RSF1 has been shown to be involved in the regulation of cellular processes that are important for the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that RSF1 may be a potential drug target for these diseases as well.

Overall, while more research is needed to fully understand the role of RSF1 in HCC and other diseases, it is clear that RSF1 is a protein that is of interest for further study. Further research is needed to determine the exact mechanism by which RSF1 contributes to the development and progression of HCC and to explore its potential as a drug target or biomarker.

Protein Name: Remodeling And Spacing Factor 1

Functions: Regulatory subunit of the ATP-dependent RSF-1 and RSF-5 ISWI chromatin-remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair (PubMed:12972596, PubMed:28801535). Binds to core histones together with SMARCA5, and is required for the assembly of regular nucleosome arrays by the RSF-5 ISWI chromatin-remodeling complex (PubMed:12972596). Directly stimulates the ATPase activity of SMARCA1 and SMARCA5 in the RSF-1 and RSF-5 ISWI chromatin-remodeling complexes, respectively (PubMed:28801535). The RSF-1 ISWI chromatin remodeling complex has a lower ATP hydrolysis rate than the RSF-5 ISWI chromatin-remodeling complex (PubMed:28801535). The complexes do not have the ability to slide mononucleosomes to the center of a DNA template (PubMed:28801535). Facilitates transcription of hepatitis B virus (HBV) genes by the pX transcription activator. In case of infection by HBV, together with pX, it represses TNF-alpha induced NF-kappa-B transcription activation. Represses transcription when artificially recruited to chromatin by fusion to a heterogeneous DNA binding domain (PubMed:11944984, PubMed:11788598)

The "RSF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RSF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets